AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Bruce V. Bigelow
Mar. 17--Amylin Pharmaceuticals said yesterday that federal regulators have approved the use of its drug Symlin to treat diabetes, capping a drug development process that began almost 18 years ago.
Symlin represents the first new drug for the treatment of diabetes since insulin was introduced in the 1920s. It also is San Diego-based Amylin's first product to win clearance by the U.S. Food and Drug Administration.
The FDA's approval also comes at a time of increased scrutiny on the pharmaceutical industry, after government regulators ordered at least two drugs withdrawn out of concern over dangerous side effects.
Amylin's new drug is a synthesized version of amylin, a naturally occurring hormone that is produced by the same cells in the pancreas that make insulin.
Symlin is to be used in conjunction with…